|
(Press Release From Inamed Corporation)
- Exclusive rights to Juvederm family of products in North America and
Australia, with non-exclusive rights in key European markets
- Rights to future hyaluronic acid product line extensions
- Products expand Inamed leadership and comprehensive offering of facial
rejuvenation products in key markets around the world
|
This article sponsored by: |
 |
|
SANTA BARBARA, Calif.--Jan. 12, 2004--Inamed Corporation, a global health care
company, today announced the signing of licensing agreements with Corneal
Group for the rights to develop, distribute and market the Juvederm(R)
dermal fillers family of products in specified markets around the world.
Juvederm is a full range of products based on non-animal, cross-linked
hyaluronic acid technology. The agreements include current formulations of
Juvederm as well as future hyaluronic acid product line extensions.
Under these agreements, Inamed will have the exclusive rights to develop,
market and distribute the Juvederm products in the United States, Canada and
Australia, and non-exclusive rights in France, Spain, the United Kingdom,
Italy, Germany and Switzerland. In the non-exclusive European countries,
Inamed will establish a new brand name to promote and market Juvederm.
Juvederm products are currently approved or registered in over 36 countries,
including all major European markets.
Like CosmoDerm(TM) and CosmoPlast(TM) human collagen and Hylaform(R) Gel
hyaluronic acid -- also Inamed products -- Juvederm does not require a
pre-treatment skin test in the countries where it is currently approved and
marketed.
"We are pleased to be working with a partner such as Corneal to
strengthen our global leadership position in the area of facial rejuvenation
and aesthetics," said Nick Teti, Chairman, CEO and President, Inamed
Corporation. "In countries where the Juvederm family of products is
available it has rapidly become a reliable part of physicians' array of
dermal fillers used for facial rejuvenation."
"The Juvederm products are well respected around the world," said
Waldemar Kita, President, Corneal Group. "We wanted a licensing partner with
exceptional experience and capabilities who we could trust with our
products' reputation, as well as the faith of our medical professionals and
patients. Inamed is the most qualified partner globally, and we're excited
to work with them to bring these products to more patients worldwide."
The family of Juvederm products was introduced in 2000 in Europe and in
2002 in Canada, where it was rapidly adopted by physicians as a key product
for wrinkle correction and soft tissue contouring. Juvederm is currently
available in three formulations, JUVEDERM 30, JUVEDERM 24 and JUVEDERM 18,
which are intended for use in a variety of applications in the dermis,
including wrinkles and soft tissue augmentation -- from lip augmentation and
superficial lines to frown lines and deep wrinkles.
"The Juvederm products have been very successful in my practice in
addressing some of the unmet patient needs in Canada," said Frances Jang,
MD, Dermatologist, Clinical Associate Professor, Department of Dermatology,
University of British Columbia. "They do not require a skin test, are
biocompatible, and have the highest concentration of hyaluronic acid of any
filler available today -- meaning they provide optimal aesthetics results
and greater lift to the skin. Juvederm gives me flexibility and a strong
option in the treatment for facial rejuvenation."
Inamed expects to initiate its clinical development program in the United
States and to register the products in Australia in the first half of 2004.
"As the leader in facial rejuvenation, this agreement strengthens our
already unmatched portfolio of facial rejuvenation products," said Hani
Zeini, Executive Vice President, Inamed Aesthetics. "With the addition of
the Juvederm products, Inamed is strategically positioned to provide the
most complete range of aesthetic options for patients and physicians --
Zyderm(R)/Zyplast(R) collagen, CosmoDerm(TM)/ CosmoPlast(TM) collagen,
Hylaform(R) Gel hyaluronic acid products, and our botulinum toxin Type A
product currently in clinical development. No other company offers this
breadth of facial rejuvenation products or comprehensive a pipeline."
About Juvederm
Juvederm(R) is a full range of dermal filler products based on
non-animal, cross-linked hyaluronic acid technology. This technology is
based on the delivery of a homogeneous gel-based HA, as opposed to a
particle-gel based HA, which is used in products such as Hylaform(R) Gel and
Restylane(R). The homogeneous nature of the Juvederm gel creates less
surface area for the body's enzymes to attack and thereby degrade the HA.
Currently, Juvederm is available in three formulations, JUVEDERM 30,
JUVEDERM 24 and JUVEDERM 18, which are intended for use in a variety of
applications in the dermis to treat wrinkles and soft tissue augmentation.
Hyaluronic acid (HA) is a naturally occurring substance (complex sugar)
found throughout the body in all living organisms. In the skin, hyaluronic
acid fills the space between collagen and elastin fibers -- replenishing the
natural support layers lost with aging -- while delivering essential
nutrients and hydration.
Juvederm features the highest concentration of hyaluronic acid among
existing HA based dermal filler products, including Restylane. In the
countries where Juvederm is available, it is approved for a wide range of
facial applications, from lip augmentation and superficial lines to frown
lines and deep wrinkles.
About Inamed Corporation
Inamed (Nasdaq:IMDC) is a global healthcare company with over 25 years of
experience developing, manufacturing and marketing innovative, high-quality,
science-based products. Current products include breast implants for
aesthetic augmentation and for reconstructive surgery; a range of dermal
products to treat facial wrinkles; and minimally invasive devices for
obesity intervention, including the Lap-Band System for morbid obesity. The
company's website is www.inamed.com.
Forward-Looking Statements
This press release contains, in addition to historical information,
forward-looking statements. Such statements are based on management's
current estimates and expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in the forward-looking statements. Inamed is providing
this information as of January 12, 2004, and expressly disclaims any duty to
update information contained in this press release.
Forward-looking statements in this press release include, without
limitation, express and implied statements regarding Inamed's anticipated
research and development, business development, product development, and
regulatory approval. These forward-looking statements involve risks and
uncertainties which could cause actual results to differ materially from
those expressed or implied here. Readers are referred to the documents filed
by Inamed with the Securities and Exchange Commission, specifically the most
recent reports which identify important risk factors that could cause actual
results to differ from those contained in the forward-looking statements,
including but not limited to: exposure to product liability and intellectual
property claims; exposure to liabilities that may not be adequately covered
by insurance or for which there is no insurance; potential negative
publicity concerning product safety; potential fluctuations in quarterly and
annual results; the effect of changing accounting and public reporting rules
and regulations; volatility of Inamed's stock price; changes in the economy
and consumer spending; competition from existing and/or new products;
failure or delay of clinical trials; uncertainty in receiving timely
regulatory approval or market acceptance for new products; dependence on a
single supplier for each of Inamed's silicone raw materials, bovine and
human collagen-based products, and hyaluronic acid-based products; failure
to protect Inamed's intellectual property; adverse changes in the regulatory
or legislative environment (both in the U.S. and internationally) affecting
our business; and failure of our collaborative partners to perform.
The information contained in this press release is a statement of
Inamed's present intention, belief or expectation and is based upon, among
other things, the existing regulatory environment, industry conditions,
market conditions and prices, the economy in general and Inamed's
assumptions. Inamed may change its intention, belief or expectation, at any
time and without notice, based upon any changes in such factors, in Inamed's
assumptions or otherwise. Inamed undertakes no obligation to review or
confirm analysts' expectations or estimates or to release publicly any
revisions to any forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. By including any information in this press release,
Inamed does not necessarily acknowledge that disclosure of such information
is required by applicable law or that the information is material.
Note to Editors: The product name Juvederm has an accent over the first
"e."
CONTACT: Inamed Corporation
Robert S. Vaters, 805-692-5420 (Investors)
Kelly O'Brien, 415-364-3840 (Media)
SOURCE: Inamed Corporation |
All contents copyright ©2000-2010
- Cosmetic Surgery News - All rights reserved.